Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations.
Phase of Trial: Phase II
Latest Information Update: 31 May 2017
At a glance
- Drugs Apabetalone (Primary)
- Indications Coronary artery disease; Low HDL cholesterol
- Focus Therapeutic Use
- Acronyms SUSTAIN
- Sponsors Resverlogix Corporation
- 07 Jun 2017 Biomarkers information updated
- 31 May 2017 According to a Resverlogix Corporation media release, results from the post-hoc analysis of SUSTAIN and ASSURE trials will be presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress 2017.
- 09 Nov 2015 Results from the post-hoc analysis of SUSTAIN and ASSURE trials comparing data between patients with and without MACE were presented at the American Society of Nephrology (ASN) Kidney Week conference.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History